Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Sarepta Therapeutics Inc (SRPT) Stock: “Eteplirsen Approval Controversy Rages On”

If you follow Sarepta Therapeutics Inc (NASDAQ:SRPT), you know about Eteplirsen. The treatment is designed to treat several diseases, including Duchenne muscular dystrophy. Recently, the FDA granted accelerated approval for the treatment. However, finalized approval is still in question and SRPT investors aren’t sure what to expect.

What’s Happening

Recently, an interesting tweet came across the wire. The tweet, authored by Alicia Ault, said the following…

Eteplirsen approval controversy rages on. FDA’s J Jenkins just spent 20 mins savaging Sarepta’s data and process. #NordSummit #Duchenne”

What We’re Seeing From SRPT

Regardless of the Tweet, with regard to Sarepta Therapeutics Inc (NASDAQ:SRPT), the bulls seem to outweigh the bears in a pool that’s not worried about the hype. Currently (2:10), the stock is trading at $50.85 Per share after a gain of $1.91 Per share or 3.90% thus far today.

Abbvie ABBV biopharmaceuticals cell blood dna gene stem test biotech research

RAJ CREATIONZS / shutterstock.com

What’s Next

Right now, things are really up in the air. The truth is that Sarepta Therapeutics Inc (NASDAQ:SRPT) needs Eteplirsent to reach finalized approval, and controversy surrounding the approval could be concerning. Nonetheless, the treatment has proven through multiple trials to be effective. Considering the accelerated approval, we know that there’s something positive to it, giving it a higher chance of finalized approval. All in all, I am expecting for the FDA to approve the treatment, leading to big gains in the long run.

Follow Sarepta Therapeutics Inc. (NASDAQ:SRPT)
Trade (NASDAQ:SRPT) Now!

Don’t Miss The News

CNA Finance offers a free subscription where you get the news as fast as we can dig it up. Never miss the news again, subscribe for free.

Note: This article was written by Joshua Rodriguez, owner and founder of CNA Finance. If you would like to connect with Joshua, you can do so by emailing him at CNAFinanceHelp@gmail.com!

Loading Comments...